Alnylam Pharmaceuticals (NASDAQ:ALNY) Stock Rating Lowered by StockNews.com
StockNews.com cut shares of Alnylam Pharmaceuticals (NASDAQ:ALNY – Free Report) from a buy rating to a hold rating in a ...
EurekAlert!50m
A cause of hyperinflammatory response in lethal COVID-19 identified
As part of the COVID-19 International Research Team, researchers at the Johns Hopkins Kimmel Cancer Center, Children’s Hospital of Philadelphia, the University of Pittsburgh and Weill Cornell Medicine ...
Alnylam Pharmaceuticals: Promising Advancements in Alzheimer’s Treatment with RNA Interference Therapeutics
Analyst Patrick Trucchio of H.C. Wainwright reiterated a Buy rating on Alnylam Pharma (ALNY – Research Report), boosting the price target to ...
ETF Daily News5d
Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Stake Increased by Algert Global LLC
Algert Global LLC increased its holdings in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY – Free Report) by 401.3% ...
Armed robbery in Revesby1h
Key Trigger of Lethal COVID-19 Inflammation Found
As part of the COVID-19 International Research Team, researchers at the Johns Hopkins Kimmel Cancer Center, Children's ...
Alnylam Pharma (ALNY) Gets a Buy from RBC Capital
RBC Capital analyst Luca Issi maintained a Buy rating on Alnylam Pharma (ALNY – Research Report) on November 25 and set a price target of ...
Investing6d
Alnylam shares retain Buy rating as analyst sees strong market for multiple ATTR-CM treatments
On Tuesday, Canaccord Genuity maintained a Buy rating on shares of Alnylam Pharmaceuticals (NASDAQ:ALNY), with a price target of $384.00. The firm's analyst commented on recent developments in the ...
Yahoo Finance5d
Alnylam to Webcast Presentation at Piper Sandler 36th Annual Healthcare Conference
CAMBRIDGE, Mass., November 27, 2024--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that management will present a company ...
Yahoo Finance6d
FDA Begins Review of Alnylam's sNDA for Expanded Amvuttra Use
Alnylam Pharmaceuticals ALNY announced that the FDA has accepted its supplemental new drug application (sNDA) seeking the label expansion of Amvuttra (vutrisiran) for review to treat ATTR ...
Investing4d
Alnylam Pharmaceuticals CSO sells $754,945 in stock
CAMBRIDGE, MA—Kevin Joseph Fitzgerald, the Chief Scientific Officer and Executive Vice President, Head of Research at Alnylam Pharmaceuticals , Inc. (NASDAQ:ALNY), recently sold a significant portion ...
Investing6d
Alnylam shares retain Buy rating as analyst sees strong market for multiple ATTR-CM treatments
On Tuesday, Canaccord Genuity maintained a Buy rating on shares of Alnylam Pharmaceuticals (NASDAQ:ALNY), with a price target of $384.00. The firm's analyst commented on recent developments in the ...
Check Out What Whales Are Doing With ALNY
Delving into the details, we found 5% of traders were bullish, while 84% showed bearish tendencies. Out of all the trades we spotted, 14 were puts, with a value of $931,387, and 5 were calls, valued ...